Terumo BCT Inc T-SEAL Mobile, Quantity: Each of 1 | Fisher Scientific
Mehmet Ozdemir - Finance and Administration Manager - Terumo Blood and Cell Technologies | LinkedIn
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro | Protocol (Translated to Turkish)
Terumo BCT and Marker Therapeutics received the first device FDA Emergency Use Authorization (EUA) to treat acute respiratory failure in COVID-19 patients